Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,priceHint,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IBRX,-159969000.0,383905984,53800000,,-89383000,-646000,-88288000,32445000,339000,-85906000,-85906000,,-3577000,,,,2000,339000,86245000,0,-3477000,,-89385000,-88288000,2030000.0,1625018000.0,404886000.0,-157939000.0,14838000.0,246301000.0,39000.0,910000.0,-1783033000.0,1090000.0,37000.0,12465000.0,83958000.0,74428000.0,627000.0,37000.0,117253000.0,113731000.0,822000.0,19970000.0,2047000.0,300252000.0,103000.0,19153000.0,18534000.0,-3897000.0,10489000.0,98337000.0,-1987000.0,98337000.0,39279000.0,48000.0,-69595000.0,3984000.0,20593000.0,-8045000.0,,,,39303000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,3.690686,11.2799 - 11.85,11.38,0.0,0.0,18,10,finmb_303022599,NasdaqGS,"ImmunityBio, Inc.",USD,1084289,861157,5.77,0.95688224,6.03 - 45.42,-33.62,-0.74020255,6.03,45.42,USD,2,10.989715,0.81028557,0.073731266,18.499384,-6.6993837,-0.36214092,4530090496,15,America/New_York,EDT,-14400000,NMS,0,False,False,11.8,1630526403,0.42000008,11.49,11.85,11.2799,921645,"ImmunityBio, Inc.",us_market,PRE,,,,45.42,6.03,10.99,18.5,1.08M,861.16k,383.91M,,87.96M,80.98%,7.31%,9.51M,11.96,13.99%,2.48%,9.38M,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-12,041.03%",,,1.57M,0.00,-22.20%,1.7M,-184.57M,-208.47M,,,103.93M,0.27,332.42M,,1.53,,-150.07M,,Value,92121,Healthcare,511,7,8,"ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.",San Diego,858 633 0300,CA,6,1609372800,1625097600,10,United States,http://immunitybio.com,86400,8,3530 John Hopkins Court,Biotechnology
t-1,IBRX,-187225000.0,383905984,41128000,,-80475000,451000,-79614000,32375000,139000,-73364000,-73364000,,-3168000,,,,6000,139000,73503000,0,-7111000,,-80481000,-79614000,1438000.0,1508958000.0,394764000.0,-185787000.0,15544000.0,209428000.0,38000.0,1284000.0,-1694745000.0,1061000.0,-38000.0,8096000.0,44679000.0,79863000.0,571000.0,-38000.0,99322000.0,99572000.0,1000000.0,38594000.0,5434000.0,297286000.0,131000.0,20097000.0,38928000.0,6497000.0,31845000.0,38497000.0,-1011000.0,1121000.0,9764000.0,-109000.0,-60469000.0,2972000.0,10687000.0,-7083000.0,40000000.0,-2624000.0,,19709000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,3.690686,11.2799 - 11.85,11.38,0.0,0.0,18,10,finmb_303022599,NasdaqGS,"ImmunityBio, Inc.",USD,1084289,861157,5.77,0.95688224,6.03 - 45.42,-33.62,-0.74020255,6.03,45.42,USD,2,10.989715,0.81028557,0.073731266,18.499384,-6.6993837,-0.36214092,4530090496,15,America/New_York,EDT,-14400000,NMS,0,False,False,11.8,1630526403,0.42000008,11.49,11.85,11.2799,921645,"ImmunityBio, Inc.",us_market,PRE,,,,45.42,6.03,10.99,18.5,1.08M,861.16k,383.91M,,87.96M,80.98%,7.31%,9.51M,11.96,13.99%,2.48%,9.38M,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-12,041.03%",,,1.57M,0.00,-22.20%,1.7M,-184.57M,-208.47M,,,103.93M,0.27,332.42M,,1.53,,-150.07M,,Value,92121,Healthcare,511,7,8,"ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.",San Diego,858 633 0300,CA,6,1609372800,1625097600,10,United States,http://immunitybio.com,86400,8,3530 John Hopkins Court,Biotechnology
t-2,IBRX,-236527000.0,383905984,22384000,,-36756000,1318000,-35746000,13182000,-124000,-35690000,-35690000,,-2750000,,,,-208000,-124000,35566000,0,-1066000,,-36548000,-35746000,1463000.0,623049000.0,313231000.0,-235064000.0,11318000.0,79485000.0,63000.0,1171000.0,-858420000.0,1562000.0,244000.0,7606000.0,23474000.0,49715000.0,,244000.0,28959000.0,41457000.0,,7324000.0,8093000.0,254353000.0,,7409000.0,-123000.0,-1000.0,-109000.0,-5666000.0,9336000.0,1121000.0,-33523000.0,50000.0,-27798000.0,1021000.0,-2408000.0,14000.0,-3675000.0,-2624000.0,-1991000.0,-8258000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,3.690686,11.2799 - 11.85,11.38,0.0,0.0,18,10,finmb_303022599,NasdaqGS,"ImmunityBio, Inc.",USD,1084289,861157,5.77,0.95688224,6.03 - 45.42,-33.62,-0.74020255,6.03,45.42,USD,2,10.989715,0.81028557,0.073731266,18.499384,-6.6993837,-0.36214092,4530090496,15,America/New_York,EDT,-14400000,NMS,0,False,False,11.8,1630526403,0.42000008,11.49,11.85,11.2799,921645,"ImmunityBio, Inc.",us_market,PRE,,,,45.42,6.03,10.99,18.5,1.08M,861.16k,383.91M,,87.96M,80.98%,7.31%,9.51M,11.96,13.99%,2.48%,9.38M,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-12,041.03%",,,1.57M,0.00,-22.20%,1.7M,-184.57M,-208.47M,,,103.93M,0.27,332.42M,,1.53,,-150.07M,,Value,92121,Healthcare,511,7,8,"ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.",San Diego,858 633 0300,CA,6,1609372800,1625097600,10,United States,http://immunitybio.com,86400,8,3530 John Hopkins Court,Biotechnology
t-3,IBRX,,383905984,33005000,,-51972000,1318000,-51439000,18347000,436000,-50916000,-50916000,,-2123000,,,,45000,436000,51352000,0,-1056000,,-52017000,-51439000,,,,,,,,,,,,,,,,,,,,,,,,,15283000.0,4011000.0,15274000.0,87340000.0,-3645000.0,87380000.0,56508000.0,-84000.0,-46022000.0,3498000.0,1553000.0,-9000.0,-3675000.0,-40000.0,-1991000.0,,en-US,US,EQUITY,True,Nasdaq Real Time Price,3.690686,11.2799 - 11.85,11.38,0.0,0.0,18,10,finmb_303022599,NasdaqGS,"ImmunityBio, Inc.",USD,1084289,861157,5.77,0.95688224,6.03 - 45.42,-33.62,-0.74020255,6.03,45.42,USD,2,10.989715,0.81028557,0.073731266,18.499384,-6.6993837,-0.36214092,4530090496,15,America/New_York,EDT,-14400000,NMS,0,False,False,11.8,1630526403,0.42000008,11.49,11.85,11.2799,921645,"ImmunityBio, Inc.",us_market,PRE,,,,45.42,6.03,10.99,18.5,1.08M,861.16k,383.91M,,87.96M,80.98%,7.31%,9.51M,11.96,13.99%,2.48%,9.38M,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-12,041.03%",,,1.57M,0.00,-22.20%,1.7M,-184.57M,-208.47M,,,103.93M,0.27,332.42M,,1.53,,-150.07M,,Value,92121,Healthcare,511,7,8,"ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.",San Diego,858 633 0300,CA,6,1609372800,1625097600,10,United States,http://immunitybio.com,86400,8,3530 John Hopkins Court,Biotechnology
